Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027–5033.
   PubMed Web of Science ®Google Scholar
• Lenz G, Staudt ML. Aggressive lymphomas. N Engl J Med. 2010;362:1417–1429.
   PubMed Web of Science ®Google Scholar
• Charrin S, Jouannet S, Boucheix C, et al. Tetraspanins at a glance. J Cell Sci. 2014;127:3641–3648.
   PubMed Web of Science ®Google Scholar
• Wright MD, Tomlinson MG. The ins and outs of the transmembrane 4 superfamily. Immunol Today. 1994;15:588–594.
   PubMed Web of Science ®Google Scholar
• Link MP, Bindl J, Meeker TC, et al. A unique antigen on mature B cells defined by a monoclonal antibody. J Immunol. 1986;317:3013–3018.
   Google Scholar
• Schwartz-Albiez R, Dörken B, Hofmann W, et al. The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol. 1988;140:905–914.
   PubMed Web of Science ®Google Scholar
• Van Spriel AB, Puls KL, Sofi M, et al. A regulatory role for CD37 in T cell proliferation. J Immunol. 2004;172:2953–2961.
   PubMed Web of Science ®Google Scholar
• Knobeloch KP, Wright MD, Ochsenbein AF, et al. Targeted inactivation of the tetraspanin CD37 impairs T-cell-dependent B-cell response under suboptimal costimulatory conditions. Mol Cell Biol. 2000;20:5363–5369.
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Robak P. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia. Semin Oncol. 2016;43:280–290.
   PubMed Web of Science ®Google Scholar
• Moldenhauer G. CD37. J Biol Regul Homeost Agents. 2000;14:281–283.
   PubMed Web of Science ®Google Scholar
• Press OW, Howell-Clark J, Anderson S, et al. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood. 1994;83:1390–1397.
   PubMed Web of Science ®Google Scholar
• Sheng KC, Van Spriel AB, Gartlan KH, et al. Tetraspanins CD37 and CD151 differentially regulate Ag presentation and T-cell co-stimulation by DC. Eur J Immunol. 2009;39:50–55.
   PubMed Web of Science ®Google Scholar
• Gartlan KH, Belz GT, Tarrant JM, et al. A complementary role for the tetraspanins CD37 and Tssc6 in cellular immunity. J Immunol. 2010;185:3158–3166.
   PubMed Web of Science ®Google Scholar
• Gartlan KH, Wee JL, Demaria MC, et al. Tetraspanin CD37 contributes to the initiation of cellular immunity by promoting dendritic cell migration. Eur J Immunol. 2013;43:1208–1219.
   PubMed Web of Science ®Google Scholar
• Lindmo T, Boven E, Cuttitta F, et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77–89.
   PubMed Web of Science ®Google Scholar
• Deckert J, Park PU, Chicklas S, et al. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood. 2013;122:3500–3510.
   PubMed Web of Science ®Google Scholar
• Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21:778–784.
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278–287.
   PubMed Web of Science ®Google Scholar
• Palanca-Wessels MC, Press OW. Advances in the treatment of hematologic malignancies using immunoconjugates. Blood. 2014;123:2293–2301.
   PubMed Web of Science ®Google Scholar
• Wee JL, Schulze KE, Jones EL, et al. Tetraspanin CD37 regulates β2 integrin-mediated adhesion and migration in neutrophils. J Immunol. 2015;195:5770–5779.
   PubMed Web of Science ®Google Scholar
• Teo EC, Chew Y, Phipps C. A review of monoclonal antibody therapies in lymphoma. Crit Rev Oncol Hematol. 2016;97:72–84.
   PubMed Web of Science ®Google Scholar
• Heider KH, Kiefer K, Zenz T, et al. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood. 2011;118:4159–4168.
   PubMed Web of Science ®Google Scholar
• Betrian S, Ysebaert L, Heider KH, et al. Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant/relapse-initiating CLL cells: a rationale for combination treatment. Blood Cancer J. 2016;6:e496.
   PubMed Web of Science ®Google Scholar
• Byrd J, Lapalombella R, Ramanunni A, et al. Effect of CD37 small modular immuno-pharmaceutical (SMIP) on direct apoptosis in chronic lymphocytic leukemia cells via transcriptional up-regulation of the BH3 family member BIM. J Clin Oncol. 2009;27:15S.
   Web of Science ®Google Scholar
• Robak T, Robak P, Smolewski P. TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs. 2009;10:1383–1390.
   PubMed Web of Science ®Google Scholar
• Smolewski P, Robak P, Cebula-Obrzut B, et al. Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies. Eur J Cancer. 2014;50:2677–2684.
   PubMed Web of Science ®Google Scholar
• Baum PR, Cerveny C, Gordon B, et al. Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27: 8571.
   Web of Science ®Google Scholar
• Zhao X, Lapalombella R, Joshi T, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood. 2007;110:2569–2577.
   PubMed Web of Science ®Google Scholar
• Pereira DS, Guevara CI, Jin L, et al. AGS67E, an anti-CD37 monomethyl auristatin E antibody-drug conjugate as a potential therapeutic for B/T-cell malignancies and AML: a new role for CD37 in AML. Mol Cancer Ther. 2014;14:1650–1660.
   Web of Science ®Google Scholar
• Robak T. Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. Expert Rev Hematol. 2014;7:841–857.
   PubMed Web of Science ®Google Scholar
• Buchsbaum DJ, Wahl RL, Normolle DP, et al. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt’s lymphoma xenografts. Cancer Res. 1992;52:6476–6481.
   PubMed Web of Science ®Google Scholar
• Eary JF, Press OW, Badger CC, et al. Imaging and treatment of B-cell lymphoma. J Nucl Med. 1990;31:1257–1268.
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol. 1992;10:1696–1711.
   PubMed Web of Science ®Google Scholar
• Smeland E, Funderud S, Ruud E, et al. Characterization of two murine monoclonal antibodies reactive with human B cells. Their use in a high-yield, high-purity method for isolation of B cells and utilization of such cells in an assay for B-cell stimulating factor. Scand J Immunol. 1992;21:205–214.
   Google Scholar
• Repetto-Llamazares AH, Larsen RH, Mollatt C, et al. Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma. Curr Radiopharm. 2013;6:20–27.
   PubMedGoogle Scholar
• Dahle J, Repetto-Llamazares AH, Mollatt CS, et al. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin’s lymphoma. Anticancer Res. 2013;33:85–95.
   PubMed Web of Science ®Google Scholar
• Robak T, Hellmann A, Kloczko J, et al. Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2017;176:618–628.
   PubMed Web of Science ®Google Scholar
• Pagel JM, Spurgeon SE, Byrd JC, et al. Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients. Br J Haematol. 2015;168:38–45.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Tarantolo SR, Bellam N, et al. Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Invest New Drugs. 2014;32:1213–1225.
   PubMed Web of Science ®Google Scholar
• Sawas A, Savage KJ, Perez R, et al. A phase 1 study of the Anti-CD37 antibody-drug conjugate AGS67E in advanced lymphoid malignancies. Interim results. Blood (ASH Annual Meeting Abstracts). 2015;126:3976.
   Web of Science ®Google Scholar
• Stathis A, Freedman AS, Flinn IW, et al. A phase I study of IMGN529, an antibody-drug conjugate (ADC) targeting CD37, in adult patients with relapsed or refractory B-cell non-hodgkin’s lymphoma (NHL). Blood (ASH Annual Meeting Abstracts). 2014;124: 1760.
   Google Scholar
• Kolstad A, Madsbu U, Dahle J, et al. A phase I study of 177 lu-DOTA-HH1 (Betalutin) radioimmunotherapy for patients with relapsed CD37+ Non-Hodgkin’s B cell lymphoma. Blood (ASH Annual Meeting Abstracts). 2014;124: 3094.
   Google Scholar
• Kolstad A, Madsbu U, Beasley M, et al. 177 Lu-Lilotomab satetraxetan, a novel cd37-targeted antibody-radionuclide conjugate in relapsed non-hodgkin’s lymphoma (NHL): updated results of an ongoing phase i/ii study (LYMRIT 37-01). Blood (ASH Annual Meeting Abstracts). 2017;127: 2769
   Google Scholar
• A phase 1, open label, randomized study to assess pharmacokinetics, biodistribution and radiation dosimetry of lutetium (177Lu) lilotomab satetraxetan (Betalutin®) radioimmunotherapy in patients with relapsed non-hodgkin lymphoma. In: ClinicalTrials.gov [internet]. [cited 2018 January 6]. NML Identifier: NCT02657447 Available from: https://clinicaltrials.gov/ct2/show/NCT02657447
   Google Scholar
• Barrena S, Almeida J, Yunta M, et al. Aberrant expression of tetraspanin molecules in B‐cell chronic lymphoproliferative disorders and its correlation with normal B‐cell maturation. Leukemia. 2015;19:1376–1383.
   Google Scholar
• Rafiq S, Siadak A, Butchar JP, et al. Glycovariant anti‐CD37 monospecific protein therapeutic exhibits enhanced effector cell‐mediated cytotoxicity against chronic and acute B cell malignancies. MAbs. 2013;5:723–773.
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Yeh YY, Wang LR, et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell. 2012;21:694–708.
   PubMed Web of Science ®Google Scholar
• Robak T, Robak P. Anti-CD37 antibodies for chronic lymphocytic leukemia. Expert Opin Biol Ther. 2014;14:651–661.
   PubMed Web of Science ®Google Scholar
• Algate P, Wiens J, Nillson C, et al. TRU‐016, an anti‐CD37 SMIPTM biologic, in combination with other therapeutic drugs in models of non‐hodgkin’s lymphoma. Blood (ASH Annual Meeting Abstracts). 2010;116: 3931.
   Google Scholar
• McMahan CFH, Miller R, Gordon B, et al. Evaluation of otlertuzumab (TRU‐016), an anti‐CD37 ADAPTIRTM therapeutic in preclinical combination studies with kinase inhibitors and a next generation anti‐CD20 Mab in vitro and in animal models of non‐hodgkin’s lymphoma. Blood (ASH Annual Meeting Abstracts). 2014;124: 3333.
   Google Scholar